ClinicalTrials.Veeva

Menu
P

Peninsula Research Associates, Inc. | Rolling Hills Estates, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lisdexamfetamine dimesylate
Methylphenidate Hydrochloride
LY3305677
Guanfacine Hydrochloride
LY3841136
LDX
SPD503
Pf-04965842
Omalizumab
PF-03715455

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 52 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for redu...

Invitation-only
Peanut Allergy
Peanut-Induced Anaphylaxis
Biological: Placebo
Biological: PVX-108

The primary objectives of this study are to:* estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6...

Enrolling
Respiratory Syncytial Virus Infections
Biological: PIV5-vectored RSV Vaccine (BLB-201) Low Dose
Drug: Placebo

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting
COVID-19
Biological: mRNA-1273.222
Biological: mRNA-1283.222

The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1 and Coh...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1345
Biological: Placebo

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic k...

Enrolling
Overweight or Obesity
CKD
Drug: Placebo
Drug: Retatrutide

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Brief Summary of Stage 1:The purpose Stage 1 (Phase I/IIa) is to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 d...

Active, not recruiting
Respiratory Syncytial Virus Immunization
Biological: RSV vaccine candiate formulation 1
Biological: RSV vaccine candidate formulation 2

The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory sy...

Active, not recruiting
Healthy Volunteers
Human Metapneumovirus
Biological: RSV/hMPV vaccine candidate Dose B
Biological: RSV/hMPV vaccine candidate Dose A

The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent...

Active, not recruiting
COVID-19
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Biological: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)

Trial sponsors

Shire logo
Pfizer logo
A
Sanofi logo
Lilly logo
Moderna logo
BioNTech logo
Amgen logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems